SELLAS Life Sciences Group, Inc. 8-K

What Happened

• SELLAS Life Sciences Group, Inc. filed an 8‑K (Items 2.02 and 8.01) reporting an estimated unaudited cash and cash equivalents balance of $71.8 million as of December 31, 2025. The company notes this amount is preliminary and subject to completion of year‑end close and management review, and therefore may differ materially from audited results.
• The company also reported proceeds from the exercise of common stock warrants (approximately $0.5 million) and stated that as of January 7, 2026 it had 170,282,026 shares of common stock outstanding.

Key Details

• Estimated cash and cash equivalents: $71.8 million (unaudited, preliminary) as of December 31, 2025.
• Warrant exercise proceeds: approximately $0.5 million (reported in the 8‑K).
• Shares outstanding: 170,282,026 as of January 7, 2026.
• Filing covers Items 2.02 (results of operations/financial condition) and 8.01 (other events).

Why It Matters

• Cash balance is a key indicator of the company’s ability to fund operations and clinical or development programs; investors use it to assess near‑term liquidity and runway.
• The cash figure is preliminary and unaudited—final audited financial statements may show a materially different amount, so investors should watch for the completed year‑end filings.
• Proceeds from warrant exercises and the reported share count affect dilution and outstanding share base, which are relevant for ownership percentages and per‑share metrics.